[(2R,3S,4R,5R)-5-乙酰氨基-2,3,4-三羟基-6-氧代己基]氢硫酸盐 | 10356-99-7

• 分子结构分类: 有机化合物 - 有机氧化合物
• 中文名称: [(2R,3S,4R,5R)-5-乙酰氨基-2,3,4-三羟基-6-氧代己基]氢硫酸盐
• 英文名称: N-Acetyl-D-glucosamin-monosulfat
• 英文别名: 2-Acetamido-2-deoxy-D-glucose-6-sulfat；N-Acetyl-D-glucosamin-6-sulfonsaeure；N-acetyl-glucosamine 6-sulfate；2-Deoxy-2-[(1-hydroxyethylidene)amino]-6-O-sulfohexose；[(2R,3S,4R,5R)-5-acetamido-2,3,4-trihydroxy-6-oxohexyl] hydrogen sulfate
• CAS: 10356-99-7
• 化学式: C₈H₁₅NO₉S
• 分子量: 301.274
• InChiKey: NHZWETQZLORZIR-LXGUWJNJSA-N

物化性质

• 熔点：
  120 °C (decomp)
• 密度：
  1.648±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -3.8
• 重原子数：
  19
• 可旋转键数：
  8
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.75
• 拓扑面积：
  179
• 氢给体数：
  5
• 氢受体数：
  9

文献信息

• Measurement of biosynthesis and breakdown rates of biological molecules that are inaccessible or not easily accessible to direct sampling, non-invasively, by label incorporation into metabolic derivatives and catabolitic products
  申请人：——

  公开号：US20030228259A1

  公开（公告）日：2003-12-11

  Methods of determining rate of biosynthesis or breakdown of biological molecules from metabolic derivatives and catabolic products are disclosed herein. In particular, methods of measuring the rates of biosynthesis and breakdown of biological molecules inaccessible or not easily accessible to direct sampling by sampling metabolic derivatives and catabolic products in accessible biological samples are disclosed herein.

  本发明公开了确定生物分子生物合成或分解速率的方法，具体为通过取样可获取的生物样本中的代谢衍生物和分解产物，测量难以或不易直接取样的生物分子的生物合成和分解速率。
• [EN] CONJUGATES OF A GLYCOPROTEIN OR A GLYCAN WITH A TOXIC PAYLOAD<br/>[FR] CONJUGUÉS D'UNE GLYCOPROTÉINE OU D'UN GLYCANE AVEC UNE CHARGE TOXIQUE
  申请人：GLYKOS FINLAND OY

  公开号：WO2014177771A1

  公开（公告）日：2014-11-06

  The invention relates to a glycoprotein-toxic pay- load molecule conjugate, a toxic payload molecule- glycan conjugate, and a pharmaceutical composi- tion.The invention further relates to a method for preparing the glycoprotein-toxic payload mole- cule conjugate, the method for modulating growth of a cell population and a method of treating tu- mour cells.

  这项发明涉及一种糖蛋白-毒性载荷分子结合物、一种毒性载荷分子-糖基结合物和一种药物组合物。该发明还涉及一种制备糖蛋白-毒性载荷分子结合物的方法，一种调节细胞群体生长的方法以及一种治疗肿瘤细胞的方法。
• Oligosaccharide biomarkers for mucopolysaccharidoses and other related disorders
  申请人：Meikle John Peter

  公开号：US20060286034A1

  公开（公告）日：2006-12-21

  The present invention is related to methods for diagnosing mucopolysaccharidoses (“MPS”) and related diseases. This invention pertains to methods for identifying and quantitating biochemical markers (“biomarkers”) that are present in biological fluids or tissues of a patient having a MPS or related disorder. One aspect of the method comprises determining a target quantity of a target MPS biomarker oligosaccharide from a target biological sample taken from the target animal, and then comparing the target quantity to a reference quantity of a reference MPS biomarker oligosaccharide for the diagnosis, characterization, monitoring, and clinical management of MPS and related disease. This invention also describes a kit comprising a oligosaccharide derivatization solution; an acid solution; an internal standard; a solid phase extraction column; a solid phase extraction column wash solution; an oligosaccharide elution solution; and a set of instructions for using the kit to diagnose a MPS or related disease.

  本发明涉及诊断粘多糖病（“MPS”）及相关疾病的方法。本发明涉及一种用于识别和定量生物标志物（“生物标记物”）的方法，这些生物标记物存在于患有MPS或相关疾病的患者的生物体液或组织中。该方法的一个方面包括确定来自目标生物样本的目标动物的目标MPS生物标记物寡糖的目标量，然后将目标量与用于诊断、表征、监测和临床管理MPS和相关疾病的参考MPS生物标记物寡糖的参考量进行比较。本发明还描述了一种工具包，包括寡糖衍生物溶液；酸溶液；内部标准；固相萃取柱；固相萃取柱洗涤溶液；寡糖洗脱溶液；以及一套用于使用该工具包诊断MPS或相关疾病的说明书。
• Immunomodulating compositions for treatment of immune system disorders
  申请人：——

  公开号：US20010009680A1

  公开（公告）日：2001-07-26

  The present invention relates to a composition for use as an immunomodulator comprising small molecular weight components of less than 3000 daltons, and having the following properties: a) is extractable from bile of animals; b) is capable of stimulating monocytes and macrophages in vitro and in vivo; c) is capable of modulating tumor necrosis factor production; d) contains no measurable IL-1&agr;, IL-1&bgr;, TNF, IL-6, IL-8, IL-4, GM-CSF or IFN-&ggr;; e) has an anti-proliferative effect in a malignant mouse hybridoma cell line; f) shows no cytotoxicity to human peripheral blood mononuclear cells or lymphocytes; and g) is not an endotoxin. The invention also relates to a method of preparing the composition, its use as an immunomodulator, and its use in the treatment of diseases and conditions having an immunological component.

  本发明涉及一种用作免疫调节剂的组合物，包括小分子量成分，分子量小于3000道尔顿，并具有以下特性：a）可从动物的胆汁中提取；b）能够在体外和体内刺激单核细胞和巨噬细胞；c）能够调节肿瘤坏死因子的产生；d）不含可测量的IL-1α、IL-1β、TNF、IL-6、IL-8、IL-4、GM-CSF或IFN-γ；e）对恶性小鼠杂交瘤细胞系具有抗增殖作用；f）对人类外周血单核细胞或淋巴细胞没有细胞毒性；g）不是内毒素。该发明还涉及一种制备该组合物的方法，其用作免疫调节剂，并在治疗具有免疫成分的疾病和病况中的应用。
• Methods For Treating A Condition Characterized By Dysfunction In Protein Homeostasis
  申请人：Segatori Laura

  公开号：US20090203605A1

  公开（公告）日：2009-08-13

  Methods are provided for treating conditions characterized by dysfunction in protein homeostasis in a patient in need thereof. A method for treating a condition characterized by dysfunction in protein homeostasis in a patient in need thereof is provided which comprises administering to the patient a proteostasis regulator in an amount effective to improve or restore protein homeostasis, and to reduce or eliminate the condition in the patient or to prevent its occurrence or recurrence. The condition can be a loss of function disorder such as a lysosomal storage disease, or a gain of function disorder such as an aging associated disease.

  提供了一种用于治疗患有蛋白质稳态功能障碍的患者的方法。提供了一种治疗患有蛋白质稳态功能障碍的患者的方法，包括向患者施用一种蛋白稳态调节剂，其有效量能够改善或恢复蛋白质稳态，并减少或消除患者的疾病，或预防其发生或复发。该疾病可以是功能丧失性疾病，如溶酶体贮积病，或功能增强性疾病，如与衰老相关的疾病。